Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects

• Published in: Journal of viral hepatitis Vol. 23; no. 2; pp. 96 - 104
• Main Authors: Waring, J. F., Dumas, E. O., Abel, S., Coakley, E., Cohen, D. E., Davis, J. Wade, Podsadecki, T., Dutta, S.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.02.2016; Wiley Subscription Services, Inc
• Subjects: Anilides - therapeutic use; Antiviral agents; Antiviral Agents - therapeutic use; Antiviral drugs; Biomarkers - blood; Carbamates - therapeutic use; Drug Therapy, Combination; Genotypes; Hepacivirus - drug effects; hepatitis C virus; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Humans; Interferon; Life cycles; Macrocyclic Compounds - therapeutic use; microRNA; MicroRNAs - blood; MicroRNAs - genetics; miR-122; miRNA; Replication; Ribavirin; Ritonavir; Serum levels; Sulfonamides - therapeutic use; Uracil - analogs & derivatives; Uracil - therapeutic use; Virus Replication - genetics; hepatitis C virus; microRNA; miR-122
• ISSN: 1352-0504; 1365-2893; 1365-2893
• DOI: 10.1111/jvh.12470

Summary Circulating microRNAs (miRNA) have been intensely investigated as biomarkers in disease and therapy. Several studies have identified miR‐122 as an important regulator of HCV replication. The effect of new therapies that directly target the HCV replication life cycle on circulating microRNA l...